Nevro Named to 2022 Bloomberg Gender-Equality Index

REDWOOD CITY, Calif., Jan. 26, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has been named to the 2022 Bloomberg Gender-Equality Index (GEI).  The GEI is a modified market capitalization-weighted index that aims to track the performance of public companies committed to transparency in gender-data reporting.  This index measures gender equality across five pillars: female leadership & talent pipeline, equal pay & gender pay parity, inclusive culture, anti-sexual harassment policies, and pro-women brand.

"Our inclusion in this year's GEI is a reflection of our continued commitment to fostering a diverse and inclusive workplace," said D. Keith Grossman, Chairman, CEO and President of Nevro.  "With women comprising over 50% of our global workforce, gender parity is a top priority for our company.  We're thrilled to be recognized for our commitment to nurturing diverse talent, creating an inclusive culture, and setting a market standard for disclosing efforts to address gender inequality."

Nevro was included in this year's index for scoring at or above a global threshold established by Bloomberg to reflect disclosure and overall performance across the framework's five pillars, as well as the achievement or adoption of best-in-class statistics and policies. 

The 2022 GEI included 418 companies across 45 countries and regions.  For more information on the GEI visit: https://www.bloomberg.com/gei. 

Learn more about Nevro's culture and diversity & inclusion efforts.  

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro Corp. 

Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 80,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic trunk and limb pain and painful diabetic neuropathy. 

Senza®, Senza II®, and Senza Omnia™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.

Senza, Senza II, Senza Omnia, HFX, HXF Coach, HFX Cloud, HFX Connect, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:Julie Dewey, IRCNevro Corp.Chief Corp Communications and Investor Relations Officer650-433-3247  |  [email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-named-to-2022-bloomberg-gender-equality-index-301468999.html

SOURCE Nevro Corp.